Mylan NV  

(Public, NASDAQ:MYL)   Watch this stock  
Find more results for Mylan Technologies, Incorporated
-0.27 (-0.58%)
Pre-market: 46.62 +0.03 (0.06%)
Jul 25, 7:21AM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 46.09 - 47.06
52 week 37.59 - 67.34
Open 47.04
Vol / Avg. 1,070.00/4.33M
Mkt cap 23.68B
P/E 29.78
Div/yield     -
EPS 1.56
Shares 508.37M
Beta 1.26
Inst. own 71%
Aug 9, 2016
Q2 2016 Mylan NV Earnings Call - 4:30PM EDT - Add to calendar
Aug 9, 2016
Q2 2016 Mylan NV Earnings Release - 9:30AM EDT - Add to calendar
Jun 24, 2016
Mylan NV Annual Shareholders Meeting
Jun 7, 2016
Mylan NV at Goldman Sachs Global Healthcare Conference
May 10, 2016
Mylan NV at Bank of America Merrill Lynch Health Care Conference
May 3, 2016
Q1 2016 Mylan NV Earnings Call
May 3, 2016
Q1 2016 Mylan NV Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 0.63% 8.99%
Operating margin 4.92% 15.57%
EBITD margin - 31.50%
Return on average assets 0.25% 4.45%
Return on average equity 0.56% 13.02%
Employees 35,000 -
CDP Score - -


Unit 4, Trident Place, Mosquito Way
United Kingdom - Map
+44-1707-853000 (Phone)
+44-1707-643148 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Officers and directors

Robert J. Coury Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Rajiv Malik President, Director
Age: 53
Bio & Compensation  - Reuters
Heather M. Bresch Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Rodney L. Piatt CPA Vice Chairman of the Board, Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Kenneth Scott Parks Chief Financial Officer
Age: 52
Bio & Compensation  - Reuters
Rakesh Bamzai President - India Commercial and Emerging Markets
Bio & Compensation  - Reuters
Anthony Mauro Chief Commercial Officer
Age: 42
Bio & Compensation  - Reuters
Wendy Cameron Independent Director
Age: 55
Bio & Compensation  - Reuters
Robert J. Cindrich Independent Director
Age: 71
Bio & Compensation  - Reuters
Neil F. Dimick CPA Independent Director
Age: 66
Bio & Compensation  - Reuters